A recent study has indicated that Notch 2 is overexpressed in enzalutamide-resistant prostate cancer patients, while cleaved or activated Notch 1 and HES-1 levels were increased in enzalutamide-resistant cell line models [219]. Here, NOTCH1 is linked to prostate carcinoma.